Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab with Chemoradiotherapy in Oligometastatic ES-SCLC
NCT06177925Phase 2Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Dec 2023
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in small cell lung cancer (SCLC), sponsored by Nanfang Hospital, Southern Medical University. Started Dec 2023; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06177925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06177925.